Werewolf Therapeutics
Company Details
Status: Public
Employees: 11-50
Location:
Watertown, Massachusetts, United States
Type:
sample
Technology:
sample
sample
sample
About: Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company, with the help of its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Werewolf Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.